ARDX - Ardelyx stock rises 15% on US launch of Ibsrela for irritable bowel syndrome with constipation

Ardelyx [[ARDX, +15%]] on Monday announced the U.S. launch of Ibsrela to treat irritable bowel syndrome with constipation (IBS-C) in adults. Ardelyx (NASDAQ:ARDX) President and CEO Mike Raab said Ibsrela is the first novel mechanism therapy to be introduced for IBS-C in over a decade. Ibsrela works by inhibiting a certain protein called NHE3, which is mainly responsible for the absorption of dietary sodium. By inhibiting NHE3 the drug reduces absorption of sodium from the small intestine and colon and results in a softer stool consistency. The company said Ibsrela's approval was based on two successful phase 3 trials involving over 1,200 patients with IBS-C.

For further details see:

Ardelyx stock rises 15% on US launch of Ibsrela for irritable bowel syndrome with constipation